3rd Qtr Financial Results





























Crying-baby-010.jpg
 




























Investors are starting to flock to the high-tech BioScience arena, and clearly Esperion could be a beneficiary of this investment shift. Opportunities like this are the ones that deliver long-term performance results. The clinical unmet need is a problem seeking a solution. Primary prevention is where the money is at, right place at the right time and a little bit lucky. Some will look back and say I should’ve, they lament the past and fail to capitalize on the future.
 




Investors are starting to flock to the high-tech BioScience arena, and clearly Esperion could be a beneficiary of this investment shift. Opportunities like this are the ones that deliver long-term performance results. The clinical unmet need is a problem seeking a solution. Primary prevention is where the money is at, right place at the right time and a little bit lucky. Some will look back and say I should’ve, they lament the past and fail to capitalize on the future.

Would you put a name to this pablum.
 




Investors are starting to flock to the high-tech BioScience arena, and clearly Esperion could be a beneficiary of this investment shift. Opportunities like this are the ones that deliver long-term performance results. The clinical unmet need is a problem seeking a solution. Primary prevention is where the money is at, right place at the right time and a little bit lucky. Some will look back and say I should’ve, they lament the past and fail to capitalize on the future.

Total Horseshit!!
 








Investors are starting to flock to the high-tech BioScience arena, and clearly Esperion could be a beneficiary of this investment shift. Opportunities like this are the ones that deliver long-term performance results. The clinical unmet need is a problem seeking a solution. Primary prevention is where the money is at, right place at the right time and a little bit lucky. Some will look back and say I should’ve, they lament the past and fail to capitalize on the future.

This is playing out right before our eyes. High-tech bioscience Stocks are a huge beneficiary of lower interest rates, not to mention the massive value put on the benefits of improved health. 2024 should be a banner year as everything is falling into place. It’s good to have long term options in the bank as a reward for hard work and benefit to society.